Trial · NCT04667377
Participant flow35
How many started, completed or left each group, period by period.
1 to 20 of 35
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dose Escalation Period | STARTED | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 78 | |
| Dose Escalation Period | STARTED | 2.4 mg BI 456906 - Planned Maintenance Treatment | 78 | |
| Dose Escalation Period | STARTED | 3.6 mg BI 456906 - Planned Maintenance Treatment | 77 | |
| Dose Escalation Period | STARTED | 4.8 mg BI 456906 - Planned Maintenance Treatment | 77 | |
| Dose Escalation Period | STARTED | Placebo | 77 | |
| Dose Escalation Period | Treated During Dose Escalation Period | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 77 | |
| Dose Escalation Period | Treated During Dose Escalation Period | 2.4 mg BI 456906 - Planned Maintenance Treatment | 78 | |
| Dose Escalation Period | Treated During Dose Escalation Period | 3.6 mg BI 456906 - Planned Maintenance Treatment | 77 | |
| Dose Escalation Period | Treated During Dose Escalation Period | 4.8 mg BI 456906 - Planned Maintenance Treatment | 77 | |
| Dose Escalation Period | Treated During Dose Escalation Period | Placebo | 77 | |
| Dose Escalation Period | COMPLETED | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 55 | |
| Dose Escalation Period | COMPLETED | 2.4 mg BI 456906 - Planned Maintenance Treatment | 60 | |
| Dose Escalation Period | COMPLETED | 3.6 mg BI 456906 - Planned Maintenance Treatment | 59 | |
| Dose Escalation Period | COMPLETED | 4.8 mg BI 456906 - Planned Maintenance Treatment | 55 | |
| Dose Escalation Period | COMPLETED | Placebo | 57 | |
| Dose Escalation Period | NOT COMPLETED | 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) | 23 | |
| Dose Escalation Period | NOT COMPLETED | 2.4 mg BI 456906 - Planned Maintenance Treatment | 18 | |
| Dose Escalation Period | NOT COMPLETED | 3.6 mg BI 456906 - Planned Maintenance Treatment | 18 | |
| Dose Escalation Period | NOT COMPLETED | 4.8 mg BI 456906 - Planned Maintenance Treatment | 22 | |
| Dose Escalation Period | NOT COMPLETED | Placebo | 20 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04667377/flow